West Virginia Code § 30-5-12b

Definitions; selection of generic drug products; exceptions; records;
Open in Lexace · Ask the AI about this section
labels; manufacturing standards; rules; notice of substitution; complaints; notice
and hearing; immunity.
(a) As used in this section:
(1) "Brand name" means the proprietary or trade name selected by the manufacturer and
placed upon a drug or drug product, its container, label, or wrapping at the time of
packaging.
(2) "Covered entity" means: u
(A) Any hospital or medical service organization, insurer, health coverage plan, or health
maintenance organization licensed in the state that contracts with another entity to provide
prescription drug benefits for its customers or clients;a
(B) Any health program administered by the state iln its capacity as provider of health
coverage; or
(C) Any employer, labor union, or other group of persons organized in the state that
contracts with another entity to provide prescription drug benefits for its employees or
members.
(3) "Covered individual" means a member, participant, enrollee, contract holder, policy
holder, or beneficiary of a covered entity who is provided a prescription drug benefit by a
covered entity. The term "covered individual" includes a dependent or other person provided
a prescription drug benefit through a policy, contract, or plan for a covered individual.
(4) "Generic nVame" means the official title of a drug or drug combination for which a new
drug application, or an abbreviated new drug application, has been approved by the United
States Food and Drug Administration and is in effect.
(5) "Substitute" means to dispense a therapeutically equivalent generic drug product in the
place of the drug ordered or prescribed.
(6) "Equivalent" means drugs or drug products which are the same amounts of identical
active ingredients and same dosage form and which will provide the same therapeutic
efficacy and toxicity when administered to an individual and is approved by the United
States Food and Drug Administration.
(b) A pharmacist who receives a prescription for a brand name drug or drug product shall
substitute a less expensive equivalent generic name drug or drug product unless, in the
exercise of his or her professional judgment, the pharmacist believes that the less expensive
drug is not suitable for the particular patient: Provided, That a substitution may not be made
by the pharmacist where the prescribing practitioner indicates that, in his or her
professional judgment, a specific brand name drug is medically necessary for a particular
patient.
(c) A written prescription order shall permit the pharmacist to substitute an equivalent
generic name drug or drug product except where the prescribing practitioner has indicated
in his or her own handwriting the words "Brand Medically Necessary". The following
sentence shall be printed on the prescription form: "This prescription may be filled with a
generically equivalent drug product unless the words "Brand Medically Neceessary" are
written, in the practitioner's own handwriting, on this prescription form": Provided, That
"Brand Medically Necessary" may be indicated on the prescription orderr other than in the
prescribing practitioner's own handwriting unless otherwise required by federal mandate.
(d) A verbal prescription order shall permit the pharmacist to substitute an equivalent
generic name drug or drug product except where the prescrtibing practitioner indicates to
the pharmacist that the prescription is "Brand Necessary" or "Brand Medically Necessary".
The pharmacist shall note the instructions on the file copy of the prescription or chart order
form.
(e) A person may not by trade rule, work rule,s contract or in any other way prohibit, restrict,
limit, or attempt to prohibit, restrict, or limit the making of a generic name substitution
under the provisions of this section. An employer or his or her agent may not use coercion or
other means to interfere with the prgofessional judgment of the pharmacist in deciding which
generic name drugs or drug products shall be stocked or substituted: Provided, That this
section may not be construed eto permit the pharmacist to generally refuse to substitute less
expensive therapeutically equivalent generic drugs for brand name drugs and that any
pharmacist so refusing iLs subject to the penalties prescribed §30-5-34 of this code.
(f) A pharmacist may substitute a drug pursuant to the provisions of this section only where
there will be a savings to the purchaser. Where substitution is proper, pursuant to this
section, or where the practitioner prescribes the drug by generic name, the pharmacist
shall, consistent with his or her professional judgment, dispense the lowest retail cost-
effeWctive brand which is in stock.
(g) If a pharmacist substitutes a drug pursuant to the provisions of this section, the patient
shall receive the savings which shall be equal to the difference in the patient's acquisition
cost of the product prescribed and the acquisition cost of the substituted product: Provided,
That this subsection may not apply if the patient is a covered individual.
(h) Each pharmacy shall maintain a record of any substitution of an equivalent generic name
drug product for a prescribed brand name drug product on the file copy of a written,
electronic or verbal prescription or chart order. The record shall include the manufacturer
and generic name of the drug product selected.
(i) All drugs shall be labeled in accordance with the instructions of the practitioner.
(j) Unless the practitioner directs otherwise, the prescription label on all drugs dispensed by
the pharmacist shall indicate the generic name using abbreviations, if necessary, and either
the name of the manufacturer or packager, whichever is applicable in the pharmacist's
discretion. The same notation will be made on the original prescription retained by the
pharmacist.
(k) A pharmacist may not dispense a product under the provisions of this section unless the
manufacturer has shown that the drug has been manufactured with the folloewing minimum
good manufacturing standards and practices by:
(1) Labeling products with the name of the original manufacturer and control number;
(2) Maintaining quality control standards equal to or greater than those of the United States
Food and Drug Administration;
(3) Marking products with an identification code or moanogram; and
(4) Labeling products with an expiration date. l
(l) The West Virginia Board of Pharmacy shall promulgate rules in accordance with the
provisions of §29A-3-1 et seq. of this code which establish a formulary of generic type and
brand name drug products which are determined by the board to demonstrate significant
biological or therapeutic inequivalence and which, if substituted, would pose a threat to the
health and safety of patients receiving prescription medication. The formulary shall be
promulgated by the board within 90 days of the date of passage of this section and may be
amended in accordance with the provisions of that chapter.
(m) A pharmacist may not substitute a generic-named therapeutically equivalent drug
product for a prescri bed brand name drug product if the brand name drug product or the
generic drug Vtype is listed on the formulary established by the West Virginia Board of
Pharmacy pursuant to this article or is found to be in violation of the requirements of the
United States Food and Drug Administration.
(n) Any pharmacist who substitutes any drug shall, either personally or through his or her
agent, assistant, or employee, notify the person presenting the prescription of the
substitution. The person presenting the prescription may refuse the substitution. Upon
request the pharmacist shall relate the retail price difference between the brand name and
the drug substituted for it.
(o) Every pharmacy shall post in a prominent place that is in clear and unobstructed public
view, at or near the place where prescriptions are dispensed, a sign which shall read: "West
Virginia law requires pharmacists to substitute a less expensive generic-named
therapeutically equivalent drug for a brand name drug, if available, unless you or your
physician direct otherwise". The sign shall be printed with lettering of at least one and one-
half inches in height with appropriate margins and spacing as prescribed by the West
Virginia Board of Pharmacy.
(p) The West Virginia Board of Pharmacy shall promulgate rules in accordance with §29A-3-1
et seq. of this code setting standards for substituted drug products and obtaining compliance
with the provisions of this section. The board has the primary responsibility for enforcing the
provisions of this section.
(q) Any person may file a complaint with the West Virginia Board of Pharmacy regarding any
violation of the provisions of this article. The complaints shall be investigateed by the Board
of Pharmacy.
(r) Fifteen days after the board has notified, by registered mail, a person, firm, corporation,
or copartnership that the person, firm, corporation, or copartneruship is suspected of being in
violation of a provision of this section, the board shall hold a hearing on the matter. If, as a
result of the hearing, the board determines that a person, firtm, corporation, or
copartnership is violating any of the provisions of this section, it may, in addition to any
penalties prescribed by §30-5-22 of this code, suspend or revoke the permit of any person,
firm, corporation, or copartnership to operate a pharmacy.
(s) A pharmacist or pharmacy complying with sthe provisions of this section may not be liable
in any way for the dispensing of a generic-named therapeutically equivalent drug,
substituted under the provisions of this section, unless the generic-named therapeutically
equivalent drug was incorrectly subgstituted.
(t) In no event where the pharmacist substitutes a drug under the provisions of this section
may the prescribing physician be liable in any action for loss, damage, injury, or death of any
person occasioned by or arising from the use of the substitute drug unless the original drug
was incorrectly prescribed.
(u) Failure of a practitioner to specify that a specific brand name is necessary for a
particular patient may not constitute evidence of negligence unless the practitioner had
reasonable cause to believe that the health of the patient required the use of a certain
proWduct and no other.

‹ Prev All West Virginia sections Next ›


Lexace provides legal information, not legal advice, and no attorney–client relationship is created. Statute text is provided for general information and may not reflect the most recent amendments; verify against the official state code.